Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
J&J's combo extends patients' lives in head-to-head study with AstraZeneca's drug
Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending lives of patients with a type of lung cancer, compared to AstraZeneca's blockbuster drug Tagrisso.
Drug extends survival in lung cancer patients: J&J
The combination showed a median overall survival improvement of over one year compared to osimertinib, marking the first such survival benefit in this patient group. Overall survival, which measures the length of time patients live after starting treatment,
J&J says cancer drug combination showed survival benefit over Tagrisso
Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.
8h
Key to Getting Around With Your Infant? A Car Seat and Stroller Combo
The best car seat stroller combos for infants, including all-terrain options and some that can become a double, with choices ...
FierceBiotech
18h
Repare cans plans for phase 3 cancer combo trial in latest money-saving move
As recently as last month, the biotech had been setting out plans for a phase 3 trial of the combo treatment for later in ...
1d
on MSN
Five Guys to test new combo at select St. Louis locations
Five Guys is testing a new "Classic Combo" meal in select St. Louis region locations to celebrate their 40th anniversary, ...
1d
The Unexpected Color Combo Taking 2025 by Storm, According to Designers
For 2025, 44% of the designers polled said that plum and forest green will be the ruling color combo this year. With almost ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Minnesota Vikings
Five Guys
AstraZeneca
Anycubic
Johnson & Johnson
Feedback